Peripheral Markers of Suicidal Behavior: Current Findings and Clinical Implications
- PMID: 37859438
- PMCID: PMC10591170
- DOI: 10.9758/cpn.22.1046
Peripheral Markers of Suicidal Behavior: Current Findings and Clinical Implications
Abstract
Biomarkers of suicidal behavior (SB), particularly peripheral biomarkers, may aid in the development of preventive and intervention strategies. The peripheral biomarkers of SB should be easily accessible, cost-effective, and minimally invasive. To identify peripheral biomarkers of SB, we summarized the current knowledge related to SB biomarkers with a focus on suicidal outcomes (suicidal ideation [SI], suicide risk [SR], suicide attempt [SA], and suicide death [SD]), measured site (center or periphery), and study design (cross-sectional or longitudinal). We also evaluated the central findings to validate the findings of peripheral biomarkers of SB. We found reduced peripheral interleukin (IL)-2 levels in individuals with a recent SA, higher cerebrospinal fluid (CSF) IL-6 levels in patients with a current SR and future SD, higher CSF tumor necrosis factor-α levels for current and future SRs, higher high-sensitivity C-reactive protein levels and lower peripheral total cholesterol levels for recent SAs, lower peripheral 5-HT levels for present SR, and a lower folate level for future SR and SA within 1 year. Previous studies have shown inconsistent associations of low peripheral leptin levels with SR and recent SA; therefore, further study is required. Given the multiple determinants of SB and weak associations with single biological markers, combinations of potential biological markers rather than single markers may improve the screening, diagnosis, and prediction of SB.
Keywords: Biomarkers; Cross-sectional studies; Longitudinal studies; Suicide.
Conflict of interest statement
Jae-Min Kim declares research support in the last 5 years from Janssen and Lundbeck. Robert Stewart declares research support in the last 5 years from Janssen, GSK and Takeda. Sung-Wan Kim declares research support in the last 5 years from Janssen, Boehringer Ingelheim, Allergan and Otsuka. All other authors report no biomedical financial interests or potential conflicts of in-terest.
References
-
- Johnston JN, Campbell D, Caruncho HJ, Henter ID, Ballard ED, Zarate CA. Suicide biomarkers to predict risk, classify diagnostic subtypes, and identify novel therapeutic targets: 5 years of promising research. Int J Neuropsychopharmacol. 2022;25:197–214. doi: 10.1093/ijnp/pyab083. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
